Latest Advances in Lung Cancer Research

Opdivo plus chemo reduces death risk by 43% pre-surgery in NSCLC patients, leading to FDA approval, with broad patient eligibility regardless of PD-L1 levels.

FDA skepticism challenges sintilimab’s approval for NSCLC, citing concerns over trial data exclusivity from China and its less favored endpoint of PFS.

FDA grants breakthrough designation to FoundationOne Tracker, an assay for detecting MRD in cancer, aiding treatment decisions and relapse monitoring.

FDA grants breakthrough designation to CLN-081, a targeted therapy for NSCLC with EGFR exon 20 mutations, showing promise in ongoing clinical trials.

[NEED EXTERNAL LINK TO ARTICLE]

Imfinzi plus chemotherapy tripled patient survival at three years in the CASPIAN Phase III trial for patients with extensive-stage SCLC.

Lack of Adherence to Treatment Guidelines for NSCLC patients was found in nearly one third of patients in a recent study.

Bone marrow damage reduced for extended stage small cell lung cancer patients with newly FDA approved Cosela.

Dr. Karen Marrone discusses the role of postoperative radiotherapy (PORT) in early-stages of non-small cell lung cancer (NSCLC).

No link to outside article.

Immunotherapy + Chemo Boosts Response for NSCLC patients with resectable tumors, new study out of Johns Hopkins University, Baltimore shows.

Sotorasib Approved for KRAS G12C NSCLC. First FDA approved treatment for KRAS-positive non small cell lung cancer.

A new genomic study from the Ohio State University Cancer Center points to new treatment approaches for small-cell lung cancer.